Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 4/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 5/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313819 | 0.91 | ARF6 (0.44) | ARF6SLC34A1PLATELANEALDH1A1 | |
| SCHEMBL10313845 | 0.86 | ARF6 (0.39) | ARF6MAPT | |
| SCHEMBL10275823 | 0.82 | ARF6 (0.46) | ARF6PLATPARP1PARP2 | |
| SCHEMBL10275271 | 0.82 | SLC34A1 (0.42) | SLC34A1PLATGAAMAPTALDH1A1 | |
| SCHEMBL10275598 | 0.81 | SLC34A1 (0.41) | SLC34A1GAAMAPTALDH1A1L3MBTL1 | |
| SCHEMBL10275761 | 0.81 | SLC34A1 (0.40) | SLC34A1GAAALDH1A1PARP1PARP2 | |
| SCHEMBL10275336 | 0.79 | ALDH1A1 (0.45) | SLC34A1PLATALDH1A1L3MBTL1 | |
| SCHEMBL10275306 | 0.78 | ARF6 (0.43) | ARF6SLC34A1PLATL3MBTL1 | |
| SCHEMBL10276170 | 0.78 | PLAT (0.45) | ARF6SLC34A1PLATMAPTALDH1A1 | |
| SCHEMBL10275294 | 0.76 | KDM1A (0.37) | SLC34A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | ARF6 3355/4885SLC34A1 474/4885PLAT 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.